Our diagnostic solutions 


Cancer-specific solution from a liquid biopsy sample

Sample type:
Turnaround time:

Liquid biopsy

2 blood samples

7 working days

Scroll down to discover

OncoSELECT Smart liquid biopsy panels with selected key genes per tumor type

The ctDNA solution for disease monitoring or therapeutic decision

OncoSELECT is a fast, minimally invasive analysis of circulating tumor DNA from a blood sample for lung (NSCLC), colon and breast (ER+ or HER2+) cancer patients.

It is the perfect tool to identify therapeutic solutions for cancer patients not able to get their tumor biopsied, to monitor the progression of their cancer and to detect treatment resistance as soon as it appears.

Sample Type:

Liquid biopsy

Recommended for:

  • Metastatic cancers of the following types:
  • - Non-small cell lung
  • - Breast (HR+ and HER2+)
  • - Colorectal

Genes panel:

72 genes


2 blood samples (2x10ml Streck tubes)


7 working days

Order a solution DOWNLOAD BROCHURE

The added value of ctDNA

Real OncoSELECT case studies

Practical details

Ordering a solution is very simple: Just log on to OncoSHARE and select your solution(s). If you don’t have a kit, we’ll send you one. After interpretation by our expert team an interactive report will be available for you on OncoSHARE . You can review, edit and/or share it.

A comprehensive and integrated report will be available trhough the OncoSHARE platform. After 7 to 10 days, depending on the test you purchased, the analysis report will be available. In a simple and interactive manner, it will guide you in selecting the most appropriate treatment based on the unique signature of the tumor.

For more information about the price in your country please contact the sales department at 

If your question is not included in the list below and/or if you would like more information about our solutions, please contact us at infos@oncodna.com, our Patient and Scientific Support teams are available to answer your questions directly from Monday to Friday. You can also reach us through the chat (icon at the bottom right corner of the window).

Other solutions we have developed for your needs

Complete solution integrating the analysis of solid and liquid biopsies

OncoDEEP analyses solid biopsies by combining nextgeneration sequencing (313 genes), IHCs to study protein expression and additional tests. This complete tumor profiling allows to predict patient response to approved or experimental targeted drugs, immunotherapies and chemotherapies. The NGS panel is accurately designed according to oncologists’ needs in their current practice. Importantly, it also includes an accurate determination of MSI, TMB and LOH. The NGS panel is regularly updated based on new findings reported in literature in order to provide patients with the most cost-effective solution.

Read more
Smart and cost-effective liquid biopsy panels with selected key genes per tumor type

OncoSTRAT&GO is an integrated approach that combines the analyses of a solid biopsy (by next-generation sequencing (313 genes), IHCs and additional tests) with the analysis of a blood biopsy. The blood profiling focuses either on the circulating tumor DNA (for deciphering tumor heterogeneity) or in DNA from blood cells (for studying specific germline gene alterations related to BRCAness phenotype that are challenging to detect in FFPE samples). OncoSTRAT&GO establishes a complete genetic profile of the tumor, which can be used to identify sensitivity or resistance to targeted therapies, chemotherapies and immunotherapies.

Read more
Personalized liquid biopsy for patients monitoring

OncoTRACE by OncoDNA is a test based on circulating tumor DNA (ctDNA) in liquid biopsies (principally blood). It is used to monitor the progression of the tumor (burden of the disease) and to detect lack of response or resistance to treatment as soon as it appears.

This assay is customized for each patient, as it contains personal cancer-specific markers and variants identified in a previous genomic analysis.

In 2013 OncoDNA became the first company to personalise a specific OncoTRACE test for every patient (a recent publication in 2017 in Nature demonstrates the efficacy of such an approach). Chrisie et al Journal of Clinical Oncology 35, no. 12 (April 20, 2017) 1274-1280.

Read more